Literature DB >> 28201972

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis.

Ivana Stojanovic1, Mirjana Dimitrijevic1, Marta Vives-Pi2, Maria Jose Mansilla2, Irma Pujol-Autonell2, Silvia Rodríguez-Fernandez2, Lenka Palova-Jelínkova3, David P Funda4, Alisa Gruden-Movsesijan5, Ljiljana Sofronic-Milosavljevic5, Catharien M U Hilkens6, Eva Martinez-Caceres2, Djordje Miljkovic7.   

Abstract

Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cell-based tolerogenic therapy; multiple sclerosis; regulatory T cells; rheumatoid arthritis; tolerogenic dendritic cells; type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28201972     DOI: 10.2174/1381612823666170214120708

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice.

Authors:  David P Funda; Jaroslav Goliáš; Tomáš Hudcovic; Hana Kozáková; Radek Špíšek; Lenka Palová-Jelínková
Journal:  Front Immunol       Date:  2018-02-16       Impact factor: 7.561

Review 2.  Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?

Authors:  David P Funda; Lenka Palová-Jelínková; Jaroslav Goliáš; Zuzana Kroulíková; Alena Fajstová; Tomáš Hudcovic; Radek Špíšek
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

Review 3.  Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies.

Authors:  Katina Schinnerling; Carlos Rosas; Lilian Soto; Ranjeny Thomas; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

4.  Ethyl Pyruvate Induces Tolerogenic Dendritic Cells.

Authors:  Neda Djedovic; María José Mansilla; Bojan Jevtić; Juan Navarro-Barriuso; Tamara Saksida; Eva M Martínez-Cáceres; Ðorđe Miljković
Journal:  Front Immunol       Date:  2019-02-07       Impact factor: 7.561

Review 5.  New Aspects of Diabetes Research and Therapeutic Development.

Authors:  Leslie S Satin; Scott A Soleimanpour; Emily M Walker
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

6.  Regulatory Dendritic Cells Induced by K313 Display Anti-Inflammatory Properties and Ameliorate Experimental Autoimmune Encephalitis in Mice.

Authors:  Yan Zhou; Xiao Leng; Xingyan Luo; Chunfen Mo; Qiang Zou; Yang Liu; Yantang Wang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.